Michael Geffner

834 total citations
13 papers, 585 citations indexed

About

Michael Geffner is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Michael Geffner has authored 13 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Hematology and 4 papers in Genetics. Recurrent topics in Michael Geffner's work include Complement system in diseases (7 papers), Blood groups and transfusion (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Michael Geffner is often cited by papers focused on Complement system in diseases (7 papers), Blood groups and transfusion (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Michael Geffner collaborates with scholars based in United States, United Kingdom and Italy. Michael Geffner's co-authors include Mingjun Huang, Marielle Cohard, Henri Bismuth, Si Nafa Si Ahmed, T Bizollon, C. Trépo, Michelle Chevallier, Janice K. Albrecht, M Reynès and Bruno Roche and has published in prestigious journals such as Blood, Gastroenterology and Hepatology.

In The Last Decade

Michael Geffner

12 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Geffner United States	8	333	307	170	86	76	13	585
Marion Mehrenberger France	11	97 0.3×	110 0.4×	126 0.7×	87 1.0×	43 0.6×	17	451
Kyoo Hyung Lee South Korea	11	83 0.2×	101 0.3×	55 0.3×	22 0.3×	51 0.7×	44	405
Pierre Vereerstraeten Belgium	8	105 0.3×	136 0.4×	75 0.4×	22 0.3×	83 1.1×	10	394
Constance Guillaud France	8	106 0.3×	120 0.4×	68 0.4×	21 0.2×	50 0.7×	18	525
F. Franzin Italy	9	556 1.7×	320 1.0×	54 0.3×	15 0.2×	34 0.4×	10	788
Gianna Mazzucco Italy	7	110 0.3×	61 0.2×	39 0.2×	140 1.6×	58 0.8×	12	381
Mónica Jiménez Spain	9	93 0.3×	135 0.4×	86 0.5×	6 0.1×	64 0.8×	12	521
Jean‐Marc Doutrelepont Belgium	11	56 0.2×	69 0.2×	241 1.4×	34 0.4×	41 0.5×	18	451
Hiroshi Harano Japan	11	67 0.2×	60 0.2×	57 0.3×	15 0.2×	22 0.3×	38	351
Pintip Ngamjanyaporn Thailand	13	31 0.1×	103 0.3×	235 1.4×	61 0.7×	24 0.3×	32	509

Countries citing papers authored by Michael Geffner

Since Specialization

Citations

This map shows the geographic impact of Michael Geffner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Geffner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Geffner more than expected).

Fields of papers citing papers by Michael Geffner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Geffner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Geffner. The network helps show where Michael Geffner may publish in the future.

Co-authorship network of co-authors of Michael Geffner

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Geffner. A scholar is included among the top collaborators of Michael Geffner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Geffner. Michael Geffner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Kulasekararaj, Austin, Antonio M. Risitano, Jaroslaw P. Maciejewski, et al.. (2021). Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 138(20). 1928–1938. 53 indexed citations

Risitano, Antonio M., Austin Kulasekararaj, Jong Wook Lee, et al.. (2020). Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 106(12). 3188–3197. 76 indexed citations

Wiles, Jason A., Manuel Galvan, Steven D. Podos, Michael Geffner, & Mingjun Huang. (2019). Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471). Current Medicinal Chemistry. 27(25). 4165–4180. 33 indexed citations

Kulasekararaj, Austin, Antonio M. Risitano, Jaroslaw P. Maciejewski, et al.. (2019). A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy. Blood. 134(Supplement_1). 3514–3514. 13 indexed citations

Browett, Peter, et al.. (2019). S864 A PHASE 2 OPEN-LABEL PROOF OF CONCEPT STUDY OF THE ORAL, SMALL MOLECULE FACTOR D INHIBITOR, ACH-4471, IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH). HemaSphere. 3(S1). 386–387. 2 indexed citations

Risitano, Antonio M., Jong Wook Lee, Rosario Notaro, et al.. (2019). Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 134(Supplement_1). 2226–2226. 5 indexed citations

Kocinsky, Hetal S., David Apelian, Michael Geffner, et al.. (2018). SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation. 33(suppl_1). i322–i322. 1 indexed citations

Huang, Mingjun, Wengang Yang, Steven D. Podos, et al.. (2017). Inhibition of complement alternative pathway by ACH-4471, the first clinical investigational orally-administered inhibitor of complement factor D. Molecular Immunology. 89. 200–201.

Sherman, Stuart, Chi-Liang Cheng, Guido Costamagna, et al.. (2009). Efficacy of Recombinant Human Interleukin-10 in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Subjects With Increased Risk. Pancreas. 38(3). 267–274. 29 indexed citations

10.

González‐Peralta, Regino P., Déirdre Kelly, Barbara Haber, et al.. (2005). Interferon Alfa-2b in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Children: Efficacy, Safety, and Pharmacokinetics *. Hepatology. 42(5). 1010–1018. 85 indexed citations

11.

Sherman, Stuart, Chiliang Chen, Guido Costamagna, et al.. (2005). Efficacy of Recombinant Human Interleukin-10 in Prevention of Acute Pancreatitis After ERCP in Subjects with Increased Risk: Randomized Prospective Multicenter Study. Gastrointestinal Endoscopy. 61(5). AB99–AB99. 2 indexed citations

12.

Samuel, Didier, T Bizollon, Cyrille Féray, et al.. (2003). Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology. 124(3). 642–650. 256 indexed citations

13.

Chutorian, Abe M., Jacqueline M.S. Winterkorn, & Michael Geffner. (2002). Anterior ischemic optic neuropathy in children: case reports and review of the literature. Pediatric Neurology. 26(5). 358–364. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact